Colleges, School and Institutes
Willingness to take PhD students
Chris Bunce directs a translational research group dedicated to the development of novel therapies for leukaemias and lymphomas. A particular focus is the exploitation of drug redeployment strategies using off-patent drugs to provide affordable therapies that can be exploited by all, including the world's poorer nations.
A particular focus in Professor Bunce’s translational leukaemia and lymphoma research is the use of old drugs for new diseases. Drug redeployment endeavours to use relatively cheap available drugs and to use them in new ways. His group's approach is to take drugs that are not considered as anti-cancer drugs and to use them in combinations that generate an anti-cancer effect. The group's most advanced project is the use of the contraceptive drug medroxyprogesterone acetate combined with a cholesterol lowering drug Bezafibrate. This remarkable drug combination is now in clinical trials for the treatment of acute myeloid leukemia here in the UK and for Burkitt lymphoma in Malawi.